Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKOTUJ)

• Drug Name: SRX246 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Huntington disease	8A01.10	Phase 2	[1]
Post-traumatic stress disorder	6B40	Phase 2	[2]
Intermittent explosive disorder	6C73	Phase 1/2	[3]
Anxiety disorder	6B00-6B0Z	Phase 1	[4]
Fear-related disorder	6B0Z	Phase 1	[4]

• Cross-matching ID:
  PubChem CID: 44428550
  TTD Drug ID: DMKOTUJ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Antagonist	[5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Vasopressin V1a receptor (V1AR)	DTT	AVPR1A	4.689	3.609	4.591	3.878

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Huntington disease
• ICD Disease Classification: 8A01.10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vasopressin V1a receptor (V1AR)	DTT	AVPR1A	8.89E-04	-0.12	-0.34

References

• [1] ClinicalTrials.gov (NCT02507284) Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT02733614) Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02055638) Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009). U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT02922166) Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans. U.S. National Institutes of Health.
• [5] Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11):3682.